115
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Low-dose IL-2 may enhance the effect of vedolizumab

ORCID Icon, , , ORCID Icon, &
Pages 1404-1405 | Received 07 Apr 2022, Accepted 21 May 2022, Published online: 14 Jun 2022
 

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Author contributions

CH Lee wrote the first draft of the manuscript. CH Lee, S Huang and B Nanan contributed to the initial laboratory work. P Hsu and RW Leong provide ideals and critiques regarding the study design and manuscript. R Nanan conceptualised the study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.